Cargando…
Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma
Immune checkpoint inhibitors (ICI) have dramatically changed the treatment of metastatic renal cell carcinoma (mRCC). Although many studies have reported biomarkers as predicting the efficacy of ICI in mRCC, they remain controversial and have challenges to apply in real-world practice. We evaluated...
Autores principales: | Kazama, Akira, Bilim, Vladimir, Tasaki, Masayuki, Anraku, Tsutomu, Kuroki, Hiroo, Shirono, Yuko, Murata, Masaki, Hiruma, Kaede, Tomita, Yoshihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701769/ https://www.ncbi.nlm.nih.gov/pubmed/36437290 http://dx.doi.org/10.1038/s41598-022-24437-6 |
Ejemplares similares
-
Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells
por: Shirono, Yuko, et al.
Publicado: (2023) -
MicroRNAs as Potential Regulators of GSK-3β in Renal Cell Carcinoma
por: Murata, Masaki, et al.
Publicado: (2023) -
Advanced Bladder Cancer: Changing the Treatment Landscape
por: Bilim, Vladimir, et al.
Publicado: (2022) -
Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment
por: Kuroki, Hiroo, et al.
Publicado: (2021) -
Development of patient-derived tumor organoids and a drug testing model for renal cell carcinoma
por: Kazama, Akira, et al.
Publicado: (2021)